Novo Nordisk Seeks Injunction Against Eli Lilly Weight-Loss Ads

Novo Nordisk (NVO) has asked a U.S. court to issue an injunction preventing Eli Lilly (LLY) from continuing its advertising campaigns for weight-loss drugs, alleging that the ads contain misleading comparisons between rival obesity treatments.

Details of the Action

According to the lawsuit, Novo Nordisk claims that Eli Lilly's ads make inaccurate claims about the efficacy of its drug Mounjaro (tirzepatide) compared to Novo Nordisk's Wegovy (semaglutide). The Danish company is seeking an immediate injunction to halt these ads, as well as monetary damages.

Company's Position

Eli Lilly has denied the allegations, stating in a statement that its ads are based on reliable scientific data and clinical trials. The company added that it will vigorously defend against the lawsuit.

Precedents and Context

The case comes amid fierce competition between the two companies in the rapidly growing obesity treatment market. Both companies have previously exchanged accusations in lawsuits related to intellectual property and comparative advertising.

Potential Financial Impact

The potential financial impact of the lawsuit has not yet been determined. However, any court ruling could affect each company's share of the obesity treatment market, which is estimated to be worth tens of billions of dollars.